Results from 13 weeks of treatment with the SGLT2-inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular risk factors. Effects on myocardial perfusion, cardiac adipose tissue volume and fluid dynamics.

Supervisors:

Prof. Caroline Kistorp, MD, PhD
Rigshospitalet

Prof. Morten Schou, MD, PhD
Herlev & Gentofte University Hospital

Prof. Finn Gustafsson, MD, PhD, DMSc
Rigshospitalet

Prof. Emeritus Jens Faber, MD, DMSc
Herlev & Gentofte University Hospital

Assessment Committee:

Ass. Prof. Lene Holmvang, MD, PhD (chair)
Rigshospitalet

Ass. Prof. Esben Søndergaard
Steno Diabetes Center Aarhus

Prof. Mikael Ryden
Karolinska Institutet